BRCA1 and breast cancer: Beside the point in a meta-analysis by Moorman et al [50], studying COC use among BRCA1 and BRCA2 mutation carriers, COC use had an elevated but non-statistically significant relationship with BC (odds ratio 1.21, 95% CI: 0.93–1.58).